Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 12, 2024

BUY
$343.0 - $410.68 $25,382 - $30,390
74 Added 11.14%
738 $300,000
Q3 2023

Nov 08, 2023

BUY
$338.18 - $362.46 $16,909 - $18,123
50 Added 8.14%
664 $230,000
Q2 2023

Jul 31, 2023

SELL
$314.42 - $351.91 $47,791 - $53,490
-152 Reduced 19.84%
614 $216,000
Q1 2023

May 01, 2023

SELL
$283.23 - $323.1 $67.8 Million - $77.4 Million
-239,515 Reduced 99.68%
766 $241,000
Q4 2022

Jan 30, 2023

SELL
$285.76 - $321.48 $6.2 Million - $6.97 Million
-21,686 Reduced 8.28%
240,281 $69.4 Million
Q2 2022

Aug 05, 2022

SELL
$234.96 - $292.55 $72.7 Million - $90.5 Million
-309,518 Reduced 54.16%
261,967 $73.8 Million
Q1 2022

May 11, 2022

SELL
$221.42 - $260.97 $10.6 Million - $12.5 Million
-47,953 Reduced 7.74%
571,485 $149 Million
Q2 2021

Aug 05, 2021

BUY
$187.49 - $221.1 $116 Million - $137 Million
619,438 New
619,438 $125 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $133B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Parnassus Investments, LLC Portfolio

Follow Parnassus Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parnassus Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parnassus Investments, LLC with notifications on news.